ArticleInfection and drug resistance2025
Efficacy and Safety of Eravacycline Combination Therapy for Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- The Efficacy and Safety of Eravacycline in the Management of Infections: A Single-Center Experience.Antibiotics (Basel, Switzerland) · 2026Article
- Real-world effectiveness and predictors of treatment failure for eravacycline in patients withFrontiers in cellular and infection microbiology · 2026Article
- Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study.Frontiers in pharmacology · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rising incidence of carbapenem-resistant Acinetobacter baumannii (CRAB) poses challenges in Intensive Care Unit (ICU) settings. Eravacycline, the first fluorocycline antibiotic introduced globally, is increasingly utilized for CRAB-related infections. This study compares eravacycline with tigecycline for CRAB pneumonia in ICU patients. Methods: This retrospective study analyzed 65 ICU patients with CRAB pneumonia treated at Henan Provincial People's Hospital from September 2023 to March 2024; the clinical efficacy and adverse reactions of eravacycline and tigecycline as target therapies were compared. Results: Both CRAB pneumonia cohorts exhibited more than 50% co-infection rates, predominantly Conclusion: Eravacycline demonstrated non-inferior efficacy to tigecycline in CRAB pneumonia treatment, with a favorable safety profile. Prompt consultation with infectious disease specialists and timely initiation of eravacycline therapy following the index culture are crucial factors in enhancing clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.